SALL2 and cancer: The cutoff value of the half-maximal inhibition concentration (IC50) for the Silmitasertib sensitivity was significantly lower in the AKP organoids than the AKP-S2KO (IC50AKP = 1.798 vs. IC50AKP-S2KO = 54.38) (Fig. 6F), confirming that Sall2-deficient cancer cells are more resistant to Silmitasertib-dependent cell death.